Accessibility to cancer clinical trials is an issue I have been working on for some time. They are a vital aspect in the fight against cancer, though many sufferers are unable to utilize them. Currently, only 4% of cancer patients enroll in trials in the US and less than 10% of those patients are minorities. This creates a real disparity in care and limits the reach of the trial. Frequently, high costs for the patients keep them from participating in trials or continuing with them. Such costs may include transportation, lodging, or child care, among others. S.2159 would clarify a protocol within the Department of Public Health confirming the FDA’s statement that reimbursement of ancillary costs is not considered inducement. Here in the Commonwealth, we are fortunate enough to have the best hospitals, many of them running innovative and cutting edge clinical trials. This legislation would expand access to these trials, making them available to more patients in need of life-saving treatments.